Arch Therapeutics Provides Year End Operational Update
FRAMINGHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a year-end operational update, including key performance metrics related to the ongoing commercialization activities for the Company’s first product, AC5® Advanced Wound System (“AC5”).
- FRAMINGHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a year-end operational update, including key performance metrics related to the ongoing commercialization activities for the Company’s first product, AC5® Advanced Wound System (“AC5”).
- A more detailed summary of key milestones and achievements from the fiscal year ended September 30, 2023 is provided below.
- At SAWC Spring 2023, Arch introduced the theme “Experience the Difference” to highlight AC5’s technology, application, wound coverage, and efficacy.
- AC5 is a synthetic self-assembling wound care product that provides clinicians with multi-modal support and utility across all phases of wound healing.